
|Articles|May 1, 2014
- BioPharm International-05-01-2014
- Volume 27
- Issue 5
Aseptic Valve Range Increases Sterility
Aseptic Valve Range Increases Sterility
Advertisement
ChargePoint AseptiSafe by ChargePoint Technology is designed to transport aseptic products or components. The valve range consists of two iterations capable of eliminating the ‘Ring of Concern’ through different methods to achieve sterility. ChargePoint AseptiSafe uses a steam-in-place process that ensures the sterilization of the internal surfaces of the valve together with the Ring of Concern. In addition, ChargePoint Aseptisafe bio uses a fast gassing system that sterilizes the valve interface in approximately six minutes.
Articles in this issue
over 12 years ago
Accelerated Stability Modelingover 12 years ago
Demand for New Vaccines Spurs Innovationover 12 years ago
Standardizing Practices for Disposablesover 12 years ago
Clinical Syringe Packages Increase Productivityover 12 years ago
Linking Drug Shortages and Quality Metricsover 12 years ago
Improving Protein Expression with Novel Systemsover 12 years ago
Integrated Single-Use Sterile and SIP Connector Provide Flexibilityover 12 years ago
India's Developing Market Offers OpportunitiesAdvertisement
Related to this article

Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.

The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.

Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.

More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.

NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.

Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.

Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
Advertisement
Advertisement


